Revisiting the outcome of adult wild-type HTT inactivation in the context of HTT lowering strategies for Huntington's disease

被引：0
|
作者：
Regio, S. [1 ]
Vachey, G. [1 ]
Duarte, F. [1 ]
Rybarikova, M. [1 ]
Sipion, M. [1 ]
Rey, M. [1 ]
Deglon, N. [1 ]
机构：
[1] Lausanne Univ Hosp, Lausanne, Switzerland
来源：
HUMAN GENE THERAPY | 2024年 / 35卷 / 3-4期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P405
引用
收藏
页码：A182 / A183
页数：2
相关论文
共 26 条
  • [1] Revisiting the outcome of adult wild-type Htt inactivation in the context of HTT-lowering strategies for Huntington's disease
    Regio, Sara
    Vachey, Gabriel
    Goni, Enrique
    Duarte, Fabio
    Rybarikova, Margareta
    Sipion, Melanie
    Rey, Maria
    Huarte, Maite
    Deglon, Nicole
    BRAIN COMMUNICATIONS, 2023, 5 (06)
  • [2] AAV-RNAi Mediated Lowering of HTT for the Treatment of Huntington's Disease
    Adams, Johanna
    Richards, Brenda
    O'Riordan, Catherine
    Goulet, Martin
    Jackson, Robert G.
    Bladon, John
    He, Ye
    Luo, Zhengyu
    Mueller, Christian
    Ramachandran, Shyam
    Elmer, Bradford
    MOLECULAR THERAPY, 2024, 32 (04) : 321 - 321
  • [3] Total Lowering of HTT Using Vectorized Antisense Oligonucleotides for the Treatment of Huntington's Disease
    Adams, Johanna
    Goulet, Martin
    Ramachandran, Shyam
    Elmer, Bradford
    Mueller, Christian
    MOLECULAR THERAPY, 2023, 31 (04) : 583 - 584
  • [4] HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation
    Traeger, Ulrike
    Andre, Ralph
    Lahiri, Nayana
    Magnusson-Lind, Anna
    Weiss, Andreas
    Grueninger, Stephan
    McKinnon, Chris
    Sirinathsinghji, Eva
    Kahlon, Shira
    Pfister, Edith L.
    Moser, Roger
    Hummerich, Holger
    Antoniou, Michael
    Bates, Gillian P.
    Luthi-Carter, Ruth
    Lowdell, Mark W.
    Bjoerkqvist, Maria
    Ostroff, Gary R.
    Aronin, Neil
    Tabrizi, Sarah J.
    BRAIN, 2014, 137 : 819 - 833
  • [5] Dysfunction of wild-type huntingtin in Huntington's Disease
    Cattaneo, E
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 60 - 60
  • [6] Effects of IONIS-HTTRx in Patients with Early Huntington's Disease, Results of the First HTT-Lowering Drug Trial
    Tabrizi, Sarah
    Leavitt, Blair
    Kordasiewicz, Holly
    Czech, Christian
    Swayze, Eric
    Norris, Daniel A.
    Baumann, Tiffany
    Gerlach, Irene
    Schobel, Scott
    Smith, Anne
    Lane, Roger
    Bennett, C. Frank
    NEUROLOGY, 2018, 90
  • [7] Discovery and Early Clinical Development of ISIS-HTTRx, the First HTT-Lowering Drug to Be Tested in Patients with Huntington's Disease
    Leavitt, Blair
    Tabrizi, Sarah
    Kordasiewicz, Holly
    Landwehrmeyer, Bernhard
    Henry, Scott
    Zanardi, Tom
    Swayze, Eric
    Norris, Daniel
    Smith, Anne
    Lane, Roger
    Bennett, Frank
    NEUROLOGY, 2016, 86
  • [8] EFFECTS OF IONIS-HTTRX (RG6042) IN PATIENTS WITH EARLY HUNTINGTON'S DISEASE, RESULTS OF THE FIRST HTT-LOWERING DRUG TRIAL
    Tabrizi, Sarah J.
    Leavitt, Blair
    Landwehrmeyer, Bernhard
    Wild, Edward
    Salt, Carsten
    Barker, Roger
    Craufurd, David
    Rickards, Hugh
    Rosser, Anne
    Priller, Josef
    Kordasiewicz, Holly
    Czech, Christian
    Swayze, Eric
    Norris, Daniel A.
    Baumann, Tiffany
    Gerlach, Irene
    Schobel, Scott
    Smith, Anne
    Lane, Roger
    Bennett, C. Frank
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 : A97 - A98
  • [9] THERAPEUTIC BENEFIT OF A HTT-LOWERING ANTISENSE OLIGONUCLEOTIDE TARGETING THE CAG-REPEAT IN THE R6/2 HUNTINGTON'S DISEASE MOUSE MODEL
    Datson, N.
    Mulders, S.
    van de Giessen, J.
    Gonzalez, A.
    van Deutekom, J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 : A94 - A95
  • [10] Wild-type huntingtin up-regulates BDNF transcription in Huntington's disease
    Journal of Neurology, 2001, 248 : 920 - 922
123